New drugs for tuberculosis treatment.

Abstract

Available data on anti-tuberculosis drug research reveal different properties of the agents and provoke speculation about future directions. Higher doses of the rifamycins are promising and are currently being evaluated in regimens of shorter duration that the isoniazid plus rifampin-based, six-to-nine month-course therapy. Moxifloxacin and gatifloxacin might shorten tuberculosis treatment as well, possibly in combination with rifapentine, while SQ109 could enhance the activity of rifampin-containing regimens. On the other hand, co-administration of moxifloxacin and PA-824 could be active against latent tuberculosis, whereas linezolid, PA-824 and TMC207 are candidates for a rifampin-free regimen in multidrug-resistant and extensively-resistant tuberculosis. Unfortunately, shorter than existent treatment regimens based on the new agents discussed here are likely to take at least another decade to be fully developed and implemented in clinical practice.

• Authors: Francesca Sánchez, José L López Colomés, Elsa Villarino, Jacques Grosset
• Journal: Enfermedades infecciosas y microbiologia clinica (Enferm Infecc Microbiol Clin) Vol. 29 Suppl 1 Pg. 47-56 (Mar 2011) ISSN: 1578-1852 [Electronic] Spain
• PMID: 21420567 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier España S.L. All rights reserved.

Chemical References

• Antitubercular Agents
• Rifampin
• rifapentine

Topics

• Animals
• Antitubercular Agents (administration & dosage, chemistry, classification, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Administration Schedule
• Drug Evaluation, Preclinical
• Drug Therapy, Combination
• Forecasting
• Guinea Pigs
• Humans
• Mice
• Primates
• Rabbits
• Rifampin (administration & dosage, analogs & derivatives, therapeutic use)
• Tuberculosis (drug therapy)